Uveitis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

Uveitis companies working in the market are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.
(Albany, USA) DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Uveitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Uveitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Uveitis market.

Request for a Free Sample Report @ Uveitis Market Outlook [https://www.delveinsight.com/report-store/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Uveitis Market Report are:

* In March 2025, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also includes other updates to the label including to the Warnings and Precautions section. As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.
* The total uveitis market size of in the 7MM was approximately USD 1,468 million in 2022 and is projected to increase during the forecast period (2023-2034).
* Leading Uveitis companies working in the market are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.
* As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
* The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
* Emerging Uveitis therapies such as TRS01, OCS-02, and RG6179 can potentially create a positive shift in the uveitis market size.
* On September 23, 2024, Priovant Therapeutics announced the enrollment of the first patients in the Phase 3 CLARITY study evaluating brepocitinib for non-anterior NIU, with the FDA granting Fast Track Designation to expedite its development.
* June 2024:- Bio-Thera Solutions- A Multicenter, Prospective, Post-marketing Evaluation of QLETLI (Adalimumab Injection) Treatment Clinical Study on Efficacy and Safety of Non-infectious Uveitis (UV). This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.

Uveitis Overview

Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, and can lead to vision loss if untreated. Uveitis symptoms typically include eye redness, pain, blurred vision, and sensitivity to light. Uveitis causes range from autoimmune disorders and infections to trauma and idiopathic origins. Uveitis diagnosis involves a comprehensive eye exam, imaging, and sometimes blood tests to determine underlying causes. Uveitis treatment usually includes corticosteroids, immunosuppressive agents, or biologics depending on severity and etiology.

Uveitis types include anterior uveitis (most common), intermediate, posterior, and panuveitis, each affecting different parts of the uveal tract. Uveitis complications can involve glaucoma, cataracts, retinal damage, or permanent vision impairment. Uveitis specialists such as ophthalmologists or uveitis experts play a key role in disease management. Uveitis management focuses on reducing inflammation, preserving vision, and preventing relapses. Uveitis prognosis varies but early detection and proper care improve outcomes significantly.

Uveitis research is advancing, with clinical trials exploring new biologics and targeted therapies. Uveitis awareness is essential to ensure early intervention and reduce the global burden of eye disease. Uveitis care requires long-term monitoring and personalized treatment plans to maintain visual health.

Learn more about Uveitis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Uveitis Treatment Market [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Uveitis Market

The Uveitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Uveitis market trends by analyzing the impact of current Uveitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Uveitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Uveitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The uveitis treatment market is experiencing significant growth, propelled by several key drivers. Foremost among these is the increasing global prevalence of uveitis, often linked to autoimmune diseases, infections, and inflammatory disorders. Advancements in therapeutic options, including biologics and targeted therapies, have enhanced treatment efficacy and patient outcomes. Additionally, heightened awareness of eye health and improved diagnostic techniques have facilitated earlier detection and intervention, further stimulating market expansion.

However, the market faces notable barriers. High treatment costs, particularly associated with advanced biologic therapies, can limit accessibility for some patients. Regulatory challenges and market access issues also pose obstacles to the introduction of new treatments. Moreover, the complexity of uveitis, with its various subtypes and underlying causes, necessitates personalized treatment approaches, complicating standardization and broad application of therapies. Addressing these challenges is crucial for sustaining growth and ensuring that advancements in uveitis treatment translate into improved patient care globally.

According to DelveInsight, the Uveitis market in 7MM is expected to witness a major change in the study period 2020-2034.

Uveitis Epidemiology

The Uveitis epidemiology section provides insights into the historical and current Uveitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Uveitis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Uveitis Epidemiology @ Uveitis Prevalence [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Uveitis Drugs Uptake

This section focuses on the uptake rate of the potential Uveitis drugs recently launched in the Uveitis market or expected to be launched in 2020-2034. The analysis covers the Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Uveitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Uveitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Pipeline Development Activities

The Uveitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Uveitis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Uveitis pipeline development activities @ Uveitis Medication and Companies [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Uveitis Therapeutics Assessment

Major key companies are working proactively in the Uveitis Therapeutics market to develop novel therapies which will drive the Uveitis treatment markets in the upcoming years are Novartis (SWX: NOVN), AngioDynamics Inc. (NASDAQ: ANGO), Roche (SWX: ROG), Eli Lilly and Company (NYSE: LLY), Acelyrin (NASDAQ: SLRN), Oculis Pharma (NASDAQ: OCS), Santen Inc (TYO: 4536), Aerie Pharmaceuticals (NASDAQ: AERI), Allergan (NYSE: AGN), Bausch Health (NYSE: BHC), Merck (NYSE: MRK), Pfizer Inc (NYSE: PFE), Teva Pharmaceutical Industries (NYSE: TEVA), EyePoint Pharmaceuticals (NASDAQ: EYPT), Astellas Pharma Inc (TYO: 4503), Bayer AG (ETR: BAYN), Tarsier Pharma (TASE: TRSR), and others.

Learn more about the emerging Uveitis therapies & key companies @ Uveitis Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/uveitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Uveitis Report Key Insights

1. Uveitis Patient Population

2. Uveitis Market Size and Trends

3. Key Cross Competition in the Uveitis Market

4. Uveitis Market Dynamics (Key Drivers and Barriers)

5. Uveitis Market Opportunities

6. Uveitis Therapeutic Approaches

7. Uveitis Pipeline Analysis

8. Uveitis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Uveitis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Uveitis Competitive Intelligence Analysis

4. Uveitis Market Overview at a Glance

5. Uveitis Disease Background and Overview

6. Uveitis Patient Journey

7. Uveitis Epidemiology and Patient Population

8. Uveitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Uveitis Unmet Needs

10. Key Endpoints of Uveitis Treatment

11. Uveitis Marketed Products

12. Uveitis Emerging Therapies

13. Uveitis Seven Major Market Analysis

14. Attribute Analysis

15. Uveitis Market Outlook (7 major markets)

16. Uveitis Access and Reimbursement Overview

17. KOL Views on the Uveitis Market

18. Uveitis Market Drivers

19. Uveitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uveitis-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-medication-therapies-nice-approvals-prevalence-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.